Kidney function and the effectiveness and safety of direct oral anticoagulants in atrial fibrillation: the KODIAK-AF study

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1148060

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The direct oral anticoagulants (DOACs) are a relatively new type of drug that are used to prevent the onset of stroke among patients with atrial fibrillation (AF). While these drugs have been demonstrated to be safe and effective among AF patients, in those AF patients with chronic kidney disease (CKD), there is uncertainty as to whether these drugs are similarly safe. This program of research will study the safety profile of DOACs in patients with AF and CKD.

Funded Activity Details

Start Date: 01-01-2018

End Date: 01-01-2019

Funding Scheme: Project Grants

Funding Amount: $451,730.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Preventive Medicine

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

anticoagulants | atrial fibrillation | kidney disease | population health | stroke prevention

Related Links